The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

"We are proud to announce that LifeMD now accepts Medicare Fee-For-Service for qualifying virtual primary care, including such care provided in our weight management program – an important step ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

U.S. President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program. The Centers for Medicare and ...

Joe Biden had proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy, however, the former US President's proposal was ...

Trump's predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy. The rule was not expected to be ...